CCEL:OTCPK (USA)

Cryo-Cell International Inc

$ 7.04 0 (0%)
Volume: 1,666 Avg Vol (1m): 1,324
Market Cap $: 54.92 Mil Enterprise Value $: 59.23 Mil
P/E (TTM): 27.08 P/B: 0.00
Earnings Power Value 8.17
Net Current Asset Value -2.52
Tangible Book -1.36
Projected FCF 5.37
Median P/S Value 5.3
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt 0.65
Equity-to-Asset -0.19
Debt-to-Equity -1.48
Debt-to-EBITDA 2.28
Interest Coverage 3.02
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.35
DISTRESS
GREY
SAFE
Beneish M-Score -2.66
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 3.61%

Profitability & Growth : 7/10

Current vs industry vs history
Operating Margin % 16.59
Net Margin % 6.40
ROA % 5.66
ROC (Joel Greenblatt) % 65.93
3-Year Total Revenue Growth Rate 11.50
3-Year Total EBITDA Growth Rate 30.00

» CCEL's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with OTCPK:CCEL

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Health Care Providers » Medical Care    NAICS : 621999    SIC : 8099
Compare BKK:WPH ASX:ZNT BKK:KDH BOM:524520 SGX:1D4 OTCPK:JRSS XTER:MAK BKK:D TSXV:IOM ROCO:4175 HKSE:08437 OTCPK:FCHS WAR:ENE JSE:RHB COL:NHL.N0000 BOM:532150 BOM:526783 WAR:EMC COL:AMSL.N0000 HKSE:02700
Traded in other countries
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. It organized in two reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. All the business activity of the group is functioned through United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.

Ratios

Current vs industry vs history
PE Ratio (TTM) 27.08
PE Ratio without NRI 27.08
Price-to-Owner-Earnings 14.82
PS Ratio 1.88
Price-to-Free-Cash-Flow 11.27
Price-to-Operating-Cash-Flow 10.76
EV-to-EBIT 11.85
EV-to-EBITDA 11.05
EV-to-Revenue 1.95
Shiller PE Ratio 129.82
Current Ratio 1.99
Quick Ratio 0.93
Days Inventory 381.43
Days Sales Outstanding 68.17
Days Payable 39.20

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 6.10

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.31
Price-to-Median-PS-Value 1.33
Earnings Yield (Joel Greenblatt) % 8.43

More Statistics

Revenue (TTM) (Mil) $ 30.49
EPS (TTM) $ 0.26
Beta 0.19
Volatility % 34.97
52-Week Range $ 5.5 - 9.3
Shares Outstanding (Mil) 7.8

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y